Contact
Header_1077x260px_About_Profil.jpg

Trustworthy AI in healthcare - it's TIME TO DELIVER

In Europe chronic diseases account for 86% of deaths and 77% of disease burden, thereby creating a tremendous challenge on societies. At the same time digitisation is bringing huge technological and cultural opportunities. In healthcare the usage of data-driven forecasts on individual and population health as by integration of artificial intelligence (AI)-enabled algorithms has the potential to revolutionise health protection and chronic care provision while securing the sustainability of healthcare systems.

Read More

Topics: The Science behind Diabetes, Treating Diabetes, Diabetes Technology

Posted by Prof. Dr. Freimut Schliess on Jan 7, 2020 5:16:00 PM
prof-dr-freimut-schliess

Profil wishes merry christmas and a happy new year 2020

Another year has passed and the Profil blog has seen many interesting articles through the last months. We have posted about events, conferences, webinars, and interesting scientific topics for clinical diabetes researchers. 

Read More

Topics: About Profil

Posted by Svenya Meister on Dec 23, 2019 3:56:00 PM
svenya-meister

Beer or wine or both – and if both, in which order?

Recent study investigates the impact of the combination and order of beer and wine on hangover severity

“Beer before wine and you’ll feel fine, wine before beer and you’ll feel queer” or in German “Bier auf Wein, das lass sein; Wein auf Bier, das rat’ ich dir” – this seems to be a common folk wisdom and regularly used recommendation with regards to alcohol beverage consumption in many countries and languages.

But is this just a saying or do we have scientific proof for this concept? Scientists from the University of Witten/Herdecke and the University of Cambridge investigated this old folklore and published the results in the American Journal of Clinical Nutrition early this year [1].

Read More

Topics: Clinical Trials in Diabetes

Posted by Dr. Daniela Lamers on Dec 10, 2019 5:11:00 PM
dr-daniela-lamers

Profil World - The clinical diabetes research newsletter - November 2019

Dear all,

Greetings from Germany! I am happy to share with you the newest edition of "Profil World" - our newsletter filled with information about clinical research in diabetes and obesity.

Read More

Topics: About Profil

Posted by Svenya Meister on Nov 26, 2019 5:18:00 PM
svenya-meister

Lipohypertrophy – New insights into an old issue?

Lipohypertrophy (LH) is a common side effect of insulin therapy in patients with diabetes mellitus. The prevalence of lipohypertrophy is high with cross-sectional studies reporting up to 64% of patients being affected, with higher numbers in type 1 diabetes. Predisposing factors for the development of lipohypertrophy include duration of insulin treatment, needle reuse frequency, BMI and incorrect injection and site rotation techniques. Particularly the latter seem to be of major importance as re-education of patients in proper injection site rotation with avoidance of LH tissue was reported to improve glycaemic control [1].

Read More

Topics: Clinical Trials in Diabetes, Diabetes Technology

Posted by Dr. Susanne Famulla on Nov 14, 2019 5:16:00 PM
dr-susanne-famulla

What news in the treatment of Type 2 diabetes was presented at EASD 2019?

The annual meeting of the European Association for the Study of Diabetes (EASD) took place this year in Barcelona, Spain. The present text offers a selection of topics relevant for the field of type 2 diabetes mellitus (T2DM) discussed during that meeting.

Read More

Topics: The Science behind Diabetes, Treating Diabetes

Posted by Dr. Jorge Arrubla on Oct 17, 2019 5:30:00 PM
dr-jorge-arrubla

Finally breakthrough in the immunological approach to type 1 diabetes

Type 1 diabetes is a T-cell mediated autoimmune disease. For more than 40 years, researchers have tried to intervene in the autoimmune process to halt or perhaps even reverse the slow destruction of insulin producing beta cells [1]. This has proven an elusive goal, but very recently FDA granted a breakthrough therapy designation to teplizumab, an anti-CD3 monoclonal antibody  [2]. The drug modifies CD8+ T lymphocytes, which are thought to be the key effector cells that kill beta cells.

Read More

Topics: Clinical Trials in Diabetes, Diabetes Technology

Posted by Prof. Hans de Vries on Oct 1, 2019 4:58:00 PM
prof-hans-de-vries

Current developments in approaches to bridging studies

Waiving Bridging studies under certain circumstances for biosimilar applications?

A bridging study is a study performed in a new region to provide pharmacodynamic or clinical data on efficacy, safety, dosage and dose regimen that will allow extrapolation of foreign clinical data to the population in the new region [1]. However, in most cases bridging studies between an original product versus a so called foreign reference or a local reference product generate costs without providing any notable benefit for the specific patient, nor notable scientific output. 

Read More

Topics: The Science behind Diabetes, Clinical Trials in Diabetes, Diabetes Technology

Posted by Dr. Grit Andersen on Sep 17, 2019 5:25:00 PM
dr-grit-andersen

iPDM Goes Europe: tangible impact on diabetes patients and care

Treatment inertia calls for an integrated personalized diabetes management: iPDM

Diabetes represents a huge and multidimensional challenge for European societes. It not only leads to premature ageing and frailty but also promotes chronic conditions like cardiovascular disease, blindness, dementia and even cancer. Despite the availability of numerous treatment options treatment inertia is still a common problem: many patents still fail to reach their treatment goals. According to the UK National Diabetes Audit data 2016- 2017, only 30% of people with type 1 diabetes and 67% of people with type 2 diabetes achieved a HbA1c target of not more than 58 mmol/l (7.5%).

Read More

Topics: The Science behind Diabetes, Treating Diabetes, Diabetes Technology

Posted by Prof. Dr. Freimut Schliess on Sep 3, 2019 5:17:00 PM
prof-dr-freimut-schliess

New PID-algorithm for automated glucose clamps

Introduction

The euglycemic, hyperinsulinemic glucose clamp is the gold standard for the determination of pharmacokinetic and pharmacodynamic (PK/PD) effects of new anti-diabetic drugs, in particular insulins. In a typical glucose clamp experiment, a drug-induced decline in blood glucose (BG) concentrations is prevented by infusing glucose at a variable rate, so that BG is "clamped" at a pre-determined target level.

Read More

Topics: Clinical Trials in Diabetes, About Profil, Diabetes Technology

Posted by Dr. Carsten Benesch on Aug 21, 2019 5:19:00 PM
dr-carsten-benesch

Subscribe to our monthly blog updates

Find out more: Glucose Clamp Webinar

Subscribe to Email Updates

Our most popular Posts